Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Hebron University · Memorial Sloan Kettering Cancer Center · +37 more institutions
Abstract
occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.
exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy.
Citation impact
- FWCI
- 63.65
- Percentile
- 100%
- References
- 41
Authors
35- PKPaul K. PaikCorresponding
Hebron University, Memorial Sloan Kettering Cancer Center, Inserm, Centre Hospitalier Universitaire de Lille
- EFEnriqueta Felip
Hebron University, Inserm, Centre Hospitalier Universitaire de Lille, Vall d'Hebron Institute of Oncology
- RVRémi Veillon
Hebron University, Inserm, Centre Hospitalier Universitaire de Lille
- HSHiroshi Sakai
Hebron University, Inserm, Centre Hospitalier Universitaire de Lille, Saitama Cancer Center
- ABAlexis B. Cortot
Hebron University, Inserm, Université de Lille, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, Centre National pour la Recherche Scientifique et Technique (CNRST)
Topics & keywords
- Medicine
- Exon
- Lung cancer
- Internal medicine
- Biopsy
- Confidence interval
- Liquid biopsy
- Exon skipping
- Good health and well-being